Search
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Spirapril
go.drugbank.com/drugs/DB01348ApprovedInvestigationalSpirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration. … ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.
Categories: Agents Acting on the Renin-Angiotensin SystemRusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … [L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113]
Trichlormethiazide
go.drugbank.com/drugs/DB01021ApprovedVet approvedA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Categories: Agents for Dermatitis, Excluding CorticosteroidsPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalAlthough the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK … [L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously
Lactitol
go.drugbank.com/drugs/DB12942Approved[A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in … [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]
Categories: Compounds used in a research, industrial, or household setting, Drugs for ConstipationPerfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536] … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.
Ferric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … [A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.
Phenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalIt promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Mixtures: Phenaphen No 3 Cap, Phenaphen No 4 CapProducts: FENOBARBITAL TABLETAS X 10 MG, FENOBARBITAL TABLETAS X 10 MG.